300683 Stock Overview
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China.
Wuhan Hiteck Biological PharmaLtd Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CN¥35.35|
|52 Week High||CN¥75.00|
|52 Week Low||CN¥29.29|
|1 Month Change||-12.61%|
|3 Month Change||-8.23%|
|1 Year Change||-15.04%|
|3 Year Change||14.66%|
|5 Year Change||-41.73%|
|Change since IPO||-25.47%|
Recent News & Updates
|300683||CN Biotechs||CN Market|
Return vs Industry: 300683 exceeded the CN Biotechs industry which returned -35.5% over the past year.
Return vs Market: 300683 exceeded the CN Market which returned -18.6% over the past year.
|300683 Average Weekly Movement||6.3%|
|Biotechs Industry Average Movement||4.8%|
|Market Average Movement||5.8%|
|10% most volatile stocks in CN Market||9.3%|
|10% least volatile stocks in CN Market||3.7%|
Stable Share Price: 300683 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 300683's weekly volatility (6%) has been stable over the past year.
About the Company
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye, an acyclovir dispensable tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository drug; Xunkeyuan, a tinidazole suppository drug; and Shufu, a nimodipine sustained release tablets. The company also provides measles virus and rubella virus nucleic acid detection kit; mycoplasma isolation and identification kit and culture tube; bacterial vaginosis rapid detection kit; measles virus IgG antibody detection kit; and coronavirus N-protein detection kit.
Wuhan Hiteck Biological PharmaLtd Fundamentals Summary
|300683 fundamental statistics|
Is 300683 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|300683 income statement (TTM)|
|Cost of Revenue||CN¥399.86m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.32|
|Net Profit Margin||5.06%|
How did 300683 perform over the long term?See historical performance and comparison
Is 300683 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 300683?
Other financial metrics that can be useful for relative valuation.
|What is 300683's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 300683's PE Ratio compare to its peers?
|300683 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
688136 Shandong Kexing Bioproducts Co.Ltd
688468 Chemclin Diagnostics
688767 Hangzhou Biotest BiotechLtd
300149 Chempartner Pharmatech
300683 Wuhan Hiteck Biological PharmaLtd
Price-To-Earnings vs Peers: 300683 is expensive based on its Price-To-Earnings Ratio (109.8x) compared to the peer average (36x).
Price to Earnings Ratio vs Industry
How does 300683's PE Ratio compare vs other companies in the CN Biotechs Industry?
Price-To-Earnings vs Industry: 300683 is expensive based on its Price-To-Earnings Ratio (109.8x) compared to the CN Biotechs industry average (29.6x)
Price to Earnings Ratio vs Fair Ratio
What is 300683's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||109.8x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 300683's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 300683 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 300683's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 300683's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Wuhan Hiteck Biological PharmaLtd forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wuhan Hiteck Biological PharmaLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of 300683’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
How has Wuhan Hiteck Biological PharmaLtd performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 300683 has a high level of non-cash earnings.
Growing Profit Margin: 300683 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 300683's earnings have declined by 50.7% per year over the past 5 years.
Accelerating Growth: 300683 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 300683 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (6.5%).
Return on Equity
High ROE: 300683's Return on Equity (2.1%) is considered low.
Discover strong past performing companies
How is Wuhan Hiteck Biological PharmaLtd's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 300683's short term assets (CN¥1.5B) exceed its short term liabilities (CN¥243.5M).
Long Term Liabilities: 300683's short term assets (CN¥1.5B) exceed its long term liabilities (CN¥82.9M).
Debt to Equity History and Analysis
Debt Level: 300683 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 300683's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 300683's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 300683's interest payments on its debt are well covered by EBIT.
Discover healthy companies
What is Wuhan Hiteck Biological PharmaLtd current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 300683's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 300683's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 300683's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 300683's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: 300683 is not paying a notable dividend for the CN market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 300683 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Ya Chen (50 yo)
Mr. Chen Ya serves as General Manager at Wuhan Hiteck Biological Pharma Co., Ltd. Mr. Chen serves as the General Manager of Yiyuan Tang Health Science and Technology Co., Ltd. He served as Deputy General M...
Experienced Board: 300683's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.1%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Wuhan Hiteck Biological Pharma Co.,Ltd's employee growth, exchange listings and data sources
- Name: Wuhan Hiteck Biological Pharma Co.,Ltd
- Ticker: 300683
- Exchange: SZSE
- Founded: 1992
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CN¥4.316b
- Shares outstanding: 122.10m
- Website: https://www.hiteck.com.cn
Number of Employees
- Wuhan Hiteck Biological Pharma Co.,Ltd
- Hite Science and Technology Park
- Economic Development Zone
- Hubei Province
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|300683||SZSE (Shenzhen Stock Exchange)||Yes||Domestic Shares||CN||CNY||Aug 2017|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/24 00:00|
|End of Day Share Price||2022/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.